RESEARCH AREAS
The Subramanian lab works in the fields of innate immunity and systems immunology.View→
GET IN TOUCH
We are always looking for new lab members, collaborators, and research opportunities.Contact→
The Subramanian lab works in the fields of innate immunity and systems immunology.View→
We are always looking for new lab members, collaborators, and research opportunities.Contact→
What are multi-omics? Why does our microbiome matter? What’s the difference between genetics and genomics? What is a digital twin? ISB and Seattle Science Foundation have partnered to create videos answering questions like these and more, showcasing ISB scientists and their work.
Researchers have identified several factors that can be measured at the initial point of COVID-19 diagnosis that anticipate if a patient is likely to develop long COVID. They also found that mild cases of COVID-19, not just severe cases, are associated with long COVID. Their findings were published by the journal Cell.
It’s Lyme disease season in many areas of the United States, including the Northeast, the Midwest, and some places on the West Coast. In our latest Research Roundtable event, ISB Associate Professor Dr. Naeha Subramanian discussed the latest Lyme disease research conducted in her lab.
Dr. Naeha Subramanian – an expert in immunology, innate immunity, and host-pathogen interactions, and head of ISB’s Subramanian Lab – has been promoted to Associate Professor. “I am honored with this promotion and excited about the incredible research being conducted in my lab. It is a pleasure and privilege to tackle exciting questions everyday,” she said.
ISB researchers have found that a small, persistent increase in the expression of NOD1 could be responsible for higher cancer risks. The research team found that a slight 1.5-fold uptick in NOD1 expression can activate the protein and downstream signaling pathways in a manner similar to vast (30- to 200-fold) overexpression.
GeekWire published a story spotlighting ISB’s COVID-19 research. Reporter Lisa Stiffler spoke with ISB President Dr. Jim Heath about the breakneck pace ISB and all of our collaborative partners are working at to tease out COVID’s biological secrets to advance the understanding and treatment of the novel coronavirus.